SG158902A1 - Nucleic acid constructs - Google Patents

Nucleic acid constructs

Info

Publication number: SG158902A1
Authority: SG; Singapore
Prior art keywords: nucleic acid; immediate early; acid constructs; promoter sequence; hcmv
Prior art date: 2005-02-01

Application number

SG201000360-6A

Other languages

English (en)

Inventor

James Fuller

Original Assignee

Powder Ject Vaccines Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-01

Filing date

2006-02-01

Publication date

2010-02-26

2006-02-01 Application filed by Powder Ject Vaccines Inc filed Critical Powder Ject Vaccines Inc

2010-02-26 Publication of SG158902A1 publication Critical patent/SG158902A1/en

Links

108020004707 nucleic acids Proteins 0.000 title abstract 2
150000007523 nucleic acids Chemical class 0.000 title abstract 2
102000039446 nucleic acids Human genes 0.000 title abstract 2
108700002232 Immediate-Early Genes Proteins 0.000 abstract 2
108091026890 Coding region Proteins 0.000 abstract 1
238000010367 cloning Methods 0.000 abstract 1
230000037431 insertion Effects 0.000 abstract 1
238000003780 insertion Methods 0.000 abstract 1
229940065638 intron a Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

SG201000360-6A 2005-02-01 2006-02-01 Nucleic acid constructs SG158902A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64838205P	2005-02-01	2005-02-01
US67249705P	2005-04-19	2005-04-19
GBGB0507997.5A GB0507997D0 (en)	2005-02-01	2005-04-20	Nucleic acid constructs

Publications (1)

Publication Number	Publication Date
SG158902A1 true SG158902A1 (en)	2010-02-26

Family

ID=36178086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201000360-6A SG158902A1 (en)	2005-02-01	2006-02-01	Nucleic acid constructs

Country Status (20)

Country	Link
US (1)	US20100221349A1 (pt)
EP (1)	EP1850869A2 (pt)
JP (1)	JP2008528020A (pt)
KR (1)	KR20070100403A (pt)
CN (1)	CN101155597A (pt)
AP (1)	AP2007004137A0 (pt)
AU (1)	AU2006210716A1 (pt)
BR (1)	BRPI0607119A2 (pt)
CA (1)	CA2596731A1 (pt)
EA (1)	EA011557B1 (pt)
GB (1)	GB0507997D0 (pt)
IL (1)	IL184653A0 (pt)
MA (1)	MA29274B1 (pt)
MX (1)	MX2007009164A (pt)
NI (1)	NI200700191A (pt)
NO (1)	NO20074421L (pt)
SG (1)	SG158902A1 (pt)
TN (1)	TNSN07295A1 (pt)
WO (1)	WO2006082398A2 (pt)
ZA (1)	ZA200707522B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1685251E (pt) *	2003-10-10	2014-04-15	Powderject Vaccines Inc	Construções de ácido nucleico
WO2007067680A2 (en) *	2005-12-05	2007-06-14	Guava Technologies	Particle-based analyte characterization
EP1925318A1 (en) *	2006-11-20	2008-05-28	Paul-Ehrlich-Institut	Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en)	2007-06-13	2014-07-15	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Immunogenic peptides of influenza virus
CA2715078C (en) *	2007-09-26	2019-07-23	Intrexon Corporation	Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
CA2705461A1 (en)	2007-11-12	2009-06-11	The Trustees Of The University Of Pennsylvania	Vaccines against multiple subtypes of influenza virus
WO2009092038A1 (en) *	2008-01-16	2009-07-23	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Influenza dna vaccination and methods of use thereof
EP2358386B1 (en) *	2008-11-28	2016-11-02	Statens Serum Institut	Optimized influenza vaccines
ES2759015T3 (es)	2010-02-10	2020-05-07	Mayo Found Medical Education & Res	Métodos y materiales para tratar el cáncer
EP2825693B1 (en) *	2012-03-15	2018-05-30	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
CN103740715B (zh) *	2013-12-25	2016-03-23	北京大北农科技集团股份有限公司	嵌合启动子及其用途
CN103901209B (zh) *	2014-02-18	2016-05-25	王明丽	一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒
WO2015143221A1 (en)	2014-03-19	2015-09-24	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US10188713B2 (en)	2014-03-19	2019-01-29	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
CN105120042B (zh) *	2015-09-09	2019-02-12	小米科技有限责任公司	移动终端
WO2017059902A1 (en)	2015-10-07	2017-04-13	Biontech Rna Pharmaceuticals Gmbh	3' utr sequences for stabilization of rna
WO2018013704A1 (en)	2016-07-12	2018-01-18	Duke University	Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
WO2019121513A1 (en)	2017-12-18	2019-06-27	Intervet International B.V.	Swine influenza a virus vaccine
US12337025B2 (en)	2018-05-07	2025-06-24	The Administrators Of The Tulane Educational Fund	Mutated e. coli enterotoxins as anti-inflammatory agents
WO2020163768A1 (en)	2019-02-07	2020-08-13	Duke University	Stabilized 9 and 10 segmented influenza viruses as a vaccine platform and methods of making and using same
US20240084267A1 (en) *	2021-01-12	2024-03-14	Duke University	Compositions and methods for the genetic manipulation of the influenza virus
WO2024097894A1 (en) *	2022-11-04	2024-05-10	RNAimmune, Inc.	Compositions and methods of ribonucleic acid vaccines encoding nye-so-1
CN120611983B (zh) *	2025-08-11	2025-10-03	安徽省农业科学院水稻研究所	基于多指标融合的生物技术产品风险动态识别方法及系统

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3431140A1 (de) *	1984-08-24	1986-03-06	Behringwerke Ag, 3550 Marburg	Enhancer fuer eukaryotische expressionssysteme
US5100792A (en) *	1984-11-13	1992-03-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues
US4945050A (en) *	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) *	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5120657A (en) *	1986-12-05	1992-06-09	Agracetus, Inc.	Apparatus for genetic transformation
US5204253A (en) *	1990-05-29	1993-04-20	E. I. Du Pont De Nemours And Company	Method and apparatus for introducing biological substances into living cells
US5149655A (en) *	1990-06-21	1992-09-22	Agracetus, Inc.	Apparatus for genetic transformation
US5283185A (en) *	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
TW360548B (en) *	1993-04-08	1999-06-11	Powderject Res Ltd	Products for therapeutic use
DK0690732T3 (da) *	1994-01-21	2003-05-19	Powderject Vaccines Inc	Gasdrevet genindførselsinstrument
US5527928A (en) *	1994-09-30	1996-06-18	Nantz; Michael H.	Cationic transport reagents
GB0027088D0 (en) *	2000-11-06	2000-12-20	Glaxo Group Ltd	DNA expression vectors
ES2261489T3 (es) *	2000-10-13	2006-11-16	Chiron Corporation	Fragmentos de intron a de citomegalovirus.
DK1379273T3 (da) *	2000-11-27	2009-11-09	Powderject Vaccines Inc	Nukleinsyreadjuvanser
GB0118367D0 (en) *	2001-07-27	2001-09-19	Glaxosmithkline Biolog Sa	Novel use
PT1685251E (pt) *	2003-10-10	2014-04-15	Powderject Vaccines Inc	Construções de ácido nucleico
EA012066B1 (ru) *	2003-10-10	2009-08-28	Паудерджект Вэксинс, Инк.	Способ, вызывающий т-клеточный ответ

2005
- 2005-04-20 GB GBGB0507997.5A patent/GB0507997D0/en not_active Ceased
2006
- 2006-02-01 EP EP06704134A patent/EP1850869A2/en not_active Withdrawn
- 2006-02-01 JP JP2007552730A patent/JP2008528020A/ja active Pending
- 2006-02-01 MX MX2007009164A patent/MX2007009164A/es unknown
- 2006-02-01 AU AU2006210716A patent/AU2006210716A1/en not_active Abandoned
- 2006-02-01 CA CA002596731A patent/CA2596731A1/en not_active Abandoned
- 2006-02-01 KR KR1020077019899A patent/KR20070100403A/ko not_active Ceased
- 2006-02-01 CN CNA2006800110768A patent/CN101155597A/zh active Pending
- 2006-02-01 WO PCT/GB2006/000344 patent/WO2006082398A2/en not_active Ceased
- 2006-02-01 AP AP2007004137A patent/AP2007004137A0/xx unknown
- 2006-02-01 EA EA200701643A patent/EA011557B1/ru not_active IP Right Cessation
- 2006-02-01 SG SG201000360-6A patent/SG158902A1/en unknown
- 2006-02-01 US US11/815,278 patent/US20100221349A1/en not_active Abandoned
- 2006-02-01 BR BRPI0607119-8A patent/BRPI0607119A2/pt not_active IP Right Cessation
2007
- 2007-07-17 IL IL184653A patent/IL184653A0/en unknown
- 2007-07-30 TN TNP2007000295A patent/TNSN07295A1/en unknown
- 2007-07-30 NI NI200700191A patent/NI200700191A/es unknown
- 2007-08-28 MA MA30172A patent/MA29274B1/fr unknown
- 2007-08-30 NO NO20074421A patent/NO20074421L/no not_active Application Discontinuation
- 2007-08-31 ZA ZA200707522A patent/ZA200707522B/xx unknown

Also Published As

Publication number	Publication date
WO2006082398A2 (en)	2006-08-10
NI200700191A (es)	2008-02-05
MX2007009164A (es)	2008-03-13
EA200701643A1 (ru)	2008-02-28
EA011557B1 (ru)	2009-04-28
CN101155597A (zh)	2008-04-02
AP2007004137A0 (en)	2007-08-31
ZA200707522B (en)	2008-08-27
WO2006082398A3 (en)	2006-10-19
IL184653A0 (en)	2007-12-03
AU2006210716A1 (en)	2006-08-10
JP2008528020A (ja)	2008-07-31
KR20070100403A (ko)	2007-10-10
TNSN07295A1 (en)	2008-12-31
GB0507997D0 (en)	2005-05-25
CA2596731A1 (en)	2006-08-10
US20100221349A1 (en)	2010-09-02
NO20074421L (no)	2007-10-31
EP1850869A2 (en)	2007-11-07
MA29274B1 (fr)	2008-02-01
BRPI0607119A2 (pt)	2009-08-11

Publication	Publication Date	Title
TNSN07295A1 (en)	2008-12-31	Nucleic acid constructs
SG147430A1 (en)	2008-11-28	Nucleic acid constructs
MX350551B (es)	2017-09-08	Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas que expresan los mismos y metodos para usarlos.
EP2166099A3 (en)	2011-06-29	Expression enhancing intron sequences
WO2001023575A3 (en)	2001-09-07	Wuschel (wus) gene homologs
JP2010539946A5 (pt)	2011-12-15
PL1720988T3 (pl)	2012-05-31	Sposób wytwarzania nienasyconych kwasów tłuszczowych omega-3 w organizmach transgenicznych
PL1941045T3 (pl)	2011-09-30	Zastosowanie sekwencji kwasu nukleinowego do wytwarzania transgenicznej rośliny o zwiększonej tolerancji na suszę
MX2009006681A (es)	2009-07-29	Composiciones y metodos para la expresion de acidos nucleicos.
WO2000073764A3 (en)	2004-05-27	Composition and methods for the therapeutic use of an atonal-associated sequence
UA106733C2 (uk)	2014-10-10	Вектор експресії
WO2003093485A3 (en)	2004-03-25	Optimization of transgene expression in mammalian cells
JP2005523725A5 (pt)	2006-06-15
TW200628611A (en)	2006-08-16	Nucleic acid constructs
WO2001070778A3 (en)	2002-03-28	Maize glycine rich protein promoter and use thereof
EP2085475A4 (en)	2009-11-04	METHOD FOR THE PRODUCTION OF A CELL STAMM WITH ABILITY FOR TETRACYCLIN-INDUCED GENE EXPRESSION OR A CELL STEM WITH CONDITIONAL GENE KNOCKOUT AND USE OF THE CELL STRAINS
AU2294102A (en)	2002-01-30	Mutant muscle-specific enhancers
WO2007017903A3 (en)	2007-06-28	Expression vector and methods of producing high levels of proteins
WO2007046787A3 (en)	2007-07-19	Methods of reducing repeat-induced silencing of transgene expression and improved fluorescent biosensors
WO2006031780A3 (en)	2006-06-01	Promoter molecules for use in plants
WO2007121467A3 (en)	2008-12-04	Compositions and methods for increasing transgene expression in the plastids of higher plants
GB0125773D0 (en)	2001-12-19	Constructs
WO2003047532A3 (en)	2004-03-11	Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
MX2007004271A (es)	2007-06-15	Enzimas involucradas en la sintesis de triterpenos.
WO2003060135A3 (fr)	2004-03-11	Utilisation du promoteur du wdv pour une expression specifique du phloeme